EDEN PRAIRIE, Minn. / Nov 08, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2023, and introduced its financial guidance for the fiscal year ending September 30, 2024.
Fourth Quarter Fiscal 2023 Financial Summary
Fiscal Year 2023 Financial Summary
Fourth Quarter and Recent Business Highlights
“We are pleased with our revenue performance in the fourth quarter, which increased 8% year-over-year – 12% excluding SurVeil DCB license fees(1) – and ultimately exceeded our guidance range, driven by impressive contributions from both of our business segments,” said Gary Maharaj, President and CEO of Surmodics, Inc. “We complemented our fourth quarter revenue performance with notable operating results, delivering positive Adjusted EBITDA and generating cash flow from operations. In addition to our financial accomplishments, we also made strong progress with respect to each of our key strategic objectives: supporting the future commercialization of our SurVeil DCB, advancing the initial commercialization of our Pounce™ arterial thrombectomy and Sublime™ radial access platforms, and driving strong revenue growth and cash flow from our ‘core’ medical device performance coatings and In Vitro Diagnostics businesses on a combined basis.”
Mr. Maharaj continued, “Looking back on fiscal 2023, our team successfully navigated multiple challenges, while ultimately achieving our stated objectives and delivering solid financial performance. We believe we are strategically positioned for future success as a result, with a portfolio and pipeline of key product growth catalysts, durable and profitable ‘core’ businesses, more than $45 million of cash and investments to support our operations, and access to approximately $61 million in available debt capital to provide additional financial flexibility. In fiscal 2024, we are committed to executing on our growth strategy efficiently to maintain a healthy balance sheet while positioning Surmodics for strong, sustainable, long-term growth and value creation.”
Fourth Quarter Fiscal 2023 Financial Results | |||||||||||||||
| Three Months Ended September 30, |
| Increase | ||||||||||||
| 2023 |
| 2022 |
| $ |
| % | ||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
| ||||
Medical Device | $ | 21,044 |
|
| $ | 19,500 |
|
| $ | 1,544 |
|
|
| 8 | % |
In Vitro Diagnostics |
| 6,926 |
|
|
| 6,488 |
|
|
| 438 |
|
|
| 7 | % |
Total revenue | $ | 27,970 |
|
| $ | 25,988 |
|
| $ | 1,982 |
|
|
| 8 | % |
Total revenue increased $2.0 million, or 8%, to $28.0 million, compared to $26.0 million in the fourth quarter of fiscal 2022. Excluding SurVeil DCB license fee revenue,(1) total revenue increased $3.0 million, or 12%, to $26.9 million, compared to $23.9 million in the fourth quarter of fiscal 2022.
Medical Device revenue increased $1.5 million, or 8%, to $21.0 million, compared to $19.5 million in the fourth quarter of fiscal 2022. Excluding SurVeil DCB license fee revenue,(1) Medical Device revenue increased $2.5 million, or 15% to $20.0 million, compared to $17.4 million in the fourth quarter of fiscal 2022. Medical Device revenue growth was primarily driven by increased performance coating royalties and significant contributions to product sales from the Pounce thrombectomy device platform, partly offset by a decrease in proprietary specialty catheter product sales due to the completion of a customer development program. IVD revenue increased $0.4 million, or 7%, to $6.9 million, compared to $6.5 million in the fourth quarter of fiscal 2022, driven primarily by strong customer demand for microarray slide/surface products, as well as favorable order timing for distributed antigen products.
Product gross profit (defined as product sales less product costs) decreased $0.5 million, or 5%, to $8.3 million, compared to $8.8 million in the fourth quarter of fiscal 2022. Product gross margin (defined as product gross profit as a percentage of product sales) was 54.2%, compared to 61.1% in the fourth quarter of fiscal 2022. The decrease in product gross margin was primarily driven by the adverse mix impact from increased device product sales, which have lower product gross margins from under-absorption and production inefficiencies, including expiration of inventory, associated with low production volumes during the scale-up phase following initial commercialization.
Operating costs and expenses, excluding product costs, decreased $3.6 million, or 13%, to $23.4 million, compared to $27.0 million in the fourth quarter of fiscal 2022. The decrease was driven by lower research and development and selling, general and administrative expenses primarily as the result of the spending reduction plan implemented in the second quarter of fiscal 2023, as well as by delayed timing of certain investments in product development.
GAAP net income was $6.7 million, or $0.47 per diluted share, compared to GAAP net loss of $(14.7) million, or $(1.06) per diluted share in the fourth quarter of fiscal 2022. Non-GAAP net income was $7.5 million, or $0.53 per diluted share, compared to Non-GAAP net loss of $(3.7) million, or $(0.26) per diluted share in the fourth quarter of fiscal 2022.
Adjusted EBITDA was $1.7 million, compared to Adjusted EBITDA loss of $(2.5) million in the fourth quarter of fiscal 2022.
Fiscal Year 2023 Financial Results
| Fiscal Year Ended September 30, |
| Increase (Decrease) | ||||||||||||
| 2023 |
| 2022 |
| $ |
| % | ||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
| ||||
Medical Device | $ | 105,783 |
|
| $ | 72,389 |
|
| $ | 33,394 |
|
|
| 46 | % |
In Vitro Diagnostics |
| 26,801 |
|
|
| 27,562 |
|
|
| (761 | ) |
|
| (3 | )% |
Total revenue | $ | 132,584 |
|
| $ | 99,951 |
|
| $ | 32,633 |
|
|
| 33 | % |
Total revenue increased $32.6 million, or 33%, to $132.6 million, compared to $100.0 million in fiscal 2022. Excluding SurVeil DCB license fee revenue,(1) total revenue increased $8.7 million, or 9%, to $103.0 million, compared to $94.3 million in fiscal 2022.
Medical Device revenue increased $33.4 million, or 46%, to $105.8 million, compared to $72.4 million in fiscal 2022. Excluding SurVeil DCB license fee revenue,(1) Medical Device revenue increased $9.5 million, or 14% to $76.2 million, compared to $66.7 million in fiscal 2022. Medical Device revenue growth was broad-based across product sales, royalties and license fees, and research and development services. Medical Device product sales growth of 22% year-over-year was driven by increased sales of the Pounce thrombectomy and Sublime radial access platforms, performance coating reagents, and contract-manufactured balloon catheters, partly offset by decreased sales of proprietary specialty catheters due to the completion of a customer development program. IVD revenue decreased $0.8 million, or 3%, to $26.8 million, compared to $27.6 million in fiscal 2022, driven primarily by lower research and development and other revenue due to the completion of a customer development program, as well as by the impact to product sales of active management of inventory levels by certain customers.
GAAP net loss was $(1.5) million, or $(0.11) per diluted share, compared to GAAP net loss of $(27.3) million, or $(1.96) per diluted share in fiscal 2022. Non-GAAP net income was $2.2 million, or $0.16 per diluted share, compared to Non-GAAP net loss of $(13.2) million, or $(0.95) per diluted share in fiscal 2022.
Adjusted EBITDA was $21.5 million, compared to Adjusted EBITDA loss of $(5.8) million in fiscal 2022.
Balance Sheet Summary
As of September 30, 2023, Surmodics reported $45.4 million in cash and investments, $5.0 million in outstanding borrowings on its revolving credit facility, and $25.0 million in outstanding borrowings on its term loan facility. The company had access to approximately $61.0 million in additional debt capital as of September 30, 2023 under its revolving credit and term loan facilities. Surmodics reported $1.3 million of cash provided by operating activities and $0.7 million in capital expenditures in the fourth quarter of fiscal 2023.
Fiscal Year 2024 Financial Guidance
Surmodics expects fiscal 2024 total revenue to range from $116 million to $121 million, representing a decrease of (13)% to (9)% compared to fiscal 2023. Excluding SurVeil DCB license fee revenue,(1) Surmodics expects fiscal 2024 total revenue to range from $112 million to $117 million, representing an increase of 9% to 14% compared to fiscal 2023.
The company expects fiscal 2024 GAAP diluted loss per share to range from $(1.55) to $(1.20). Non-GAAP diluted loss per share in fiscal 2024 is expected to range from $(1.32) to $(0.97).
Conference Call Today at 7:00 a.m. CT (8:00 a.m. ET)
Surmodics is hosting a live webcast at 7:00 a.m. CT (8:00 a.m. ET) today to discuss fourth quarter and fiscal 2023 financial results and accomplishments, and to host a question-and-answer session. To access the webcast, please go to “Events & Presentations” under the “Investors” section of the company’s website at https://surmodics.gcs-web.com/events-and-presentations, and click on the webcast icon under “Upcoming Events.” To listen to the live teleconference, dial 800-267-6316 (international callers may dial 203-518-9814) and provide event ID SURMODICS.
An audio replay of the conference call will be available beginning at 11:00 a.m. CT today, until 11:00 a.m. CT on Wednesday, November 22, and can be accessed by dialing 877-660-6853 (international callers may dial 201-612-7415) and entering access ID 13741954. In addition, the webcast and transcript will be archived on the company’s website following the call.
About Surmodics, Inc.
Surmodics, Inc. is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development and manufacturing capabilities. The company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.
Safe Harbor for Forward-looking Statements
This press release, and disclosures related to it, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, including statements regarding: future success; our foundation for growth and commitment to executing on our growth strategy efficiently to maintain a healthy balance sheet while positioning Surmodics for strong, sustainable, long-term growth and value creation; our ability to make future draws on our term loan facility; our ability to access dept capital; expectations about Abbott’s launch and initial commercialization of the SurVeil DCB; our expected fulfillment of Abbott’s initial stocking order of the SurVeil DCB products; the potential of the SurVeil DCB to be a growth catalyst and the market opportunity for the product; our belief that Abbott is well-positioned to take advantage of attractive market dynamics for the SurVeil DCB and our commitment to supporting it; expectations about the three-year results of the TRANSCEND pivotal trial being presented; our future prospects; our product pipeline; continuing the sales momentum of our Sublime radial and Pounce arterial thrombectomy platforms in fiscal 2024; our expectations regarding our Preside coating technology; our expectations related to additional limited market evaluation cases for our Pounce venous thrombectomy system and its commercial launch; our fiscal 2024 financial guidance and related assumptions, including assumptions in our revenue guidance provided for modeling purposes, expected changes in revenues, expected license fee revenue related to the SurVeil DCB, expected product gross margins for fiscal 2024 and factors that we expect to impact product gross margins, expected operating expenses, expected interest expense, and expected tax expense; expected revenue for the first quarter of our fiscal 2024; our expected cash balance at the end of fiscal 2024 and expected uses of cash; expectations related to further borrowings during fiscal 2024 under our credit agreement; our fiscal 2024 strategic objectives; and further and future growth and value creation in the years to come, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including, without limitation: (1) our ability to successfully develop and commercialize our SurVeil DCB (including realization of the full potential benefits of our agreement with Abbott), Avess™ DCB, Sundance DCB, and other proprietary products; (2) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market, and sell products incorporating our technologies; (3) possible adverse market conditions and possible adverse impacts on our cash flows; (4) our ability to successfully and profitably commercialize our vascular intervention products; (5) supply chain constraints; (6) whether our operating expenses are effective in generating profitable revenues; (7) disruptions to our business from our plan to reduce our use of cash announced in the second quarter of fiscal 2023, the failure of such plan to achieve its objectives, or cost and expenses associated with such plan; and (8) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2022 and subsequent SEC filings. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.
Use of Non-GAAP Financial Information
In addition to reporting financial results in accordance with U.S. generally accepted accounting principles, or GAAP, Surmodics is reporting non-GAAP financial results including total revenue excluding SurVeil DCB license fee revenue, Medical Device revenue excluding SurVeil DCB license fee revenue, EBITDA and Adjusted EBITDA, non-GAAP operating (loss) income, non-GAAP operating (loss) income percentage, non-GAAP (loss) income before income taxes, non-GAAP net income (loss), and non-GAAP income (loss) per diluted share. We believe that these non-GAAP measures, when read in conjunction with the company’s GAAP financial statements, provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payouts under our executive compensation programs. We also are providing guidance on a range of non-GAAP revenue and loss per diluted share for fiscal 2024. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact on our reported financial results. As such, these non-GAAP measures should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.
Surmodics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
| Three Months Ended September 30, |
| Fiscal Year Ended September 30, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
| ||||
Product sales | $ | 15,363 |
|
| $ | 14,394 |
|
| $ | 60,614 |
|
| $ | 54,621 |
|
Royalties and license fees |
| 10,051 |
|
|
| 9,510 |
|
|
| 62,398 |
|
|
| 36,248 |
|
Research, development and other |
| 2,556 |
|
|
| 2,084 |
|
|
| 9,572 |
|
|
| 9,082 |
|
Total revenue |
| 27,970 |
|
|
| 25,988 |
|
|
| 132,584 |
|
|
| 99,951 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
| ||||
Product costs |
| 7,039 |
|
|
| 5,597 |
|
|
| 24,965 |
|
|
| 20,342 |
|
Research and development |
| 9,696 |
|
|
| 12,259 |
|
|
| 46,595 |
|
|
| 50,609 |
|
Selling, general and administrative |
| 12,807 |
|
|
| 13,779 |
|
|
| 51,884 |
|
|
| 46,935 |
|
Acquired intangible asset amortization |
| 878 |
|
|
| 966 |
|
|
| 3,537 |
|
|
| 4,150 |
|
Restructuring expense |
| — |
|
|
| — |
|
|
| 1,282 |
|
|
| — |
|
Contingent consideration (gain) expense |
| — |
|
|
| — |
|
|
| (829 | ) |
|
| 12 |
|
Total operating costs and expenses |
| 30,420 |
|
|
| 32,601 |
|
|
| 127,434 |
|
|
| 122,048 |
|
Operating (loss) income |
| (2,450 | ) |
|
| (6,613 | ) |
|
| 5,150 |
|
|
| (22,097 | ) |
Other expense, net |
| (339 | ) |
|
| (179 | ) |
|
| (2,663 | ) |
|
| (396 | ) |
(Loss) income before income taxes |
| (2,789 | ) |
|
| (6,792 | ) |
|
| 2,487 |
|
|
| (22,493 | ) |
Income tax benefit (expense) |
| 9,483 |
|
|
| (7,936 | ) |
|
| (4,023 | ) |
|
| (4,781 | ) |
Net income (loss) | $ | 6,694 |
|
| $ | (14,728 | ) |
| $ | (1,536 | ) |
| $ | (27,274 | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic income (loss) per share | $ | 0.48 |
|
| $ | (1.06 | ) |
| $ | (0.11 | ) |
| $ | (1.96 | ) |
Diluted income (loss) per share | $ | 0.47 |
|
| $ | (1.06 | ) |
| $ | (0.11 | ) |
| $ | (1.96 | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Weighted average number of shares outstanding: |
|
|
|
|
|
|
|
|
|
|
| ||||
Basic |
| 14,063 |
|
|
| 13,944 |
|
|
| 14,031 |
|
|
| 13,916 |
|
Diluted |
| 14,152 |
|
|
| 13,944 |
|
|
| 14,031 |
|
|
| 13,916 |
|
Surmodics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
| September 30, | ||||||
| 2023 |
| 2022 | ||||
Assets | (Unaudited) |
|
| (See Note) |
| ||
Current Assets: |
|
|
|
|
| ||
Cash and cash equivalents | $ | 41,419 |
|
| $ | 18,998 |
|
Available-for-sale securities |
| 3,933 |
|
|
| — |
|
Accounts receivable, net |
| 10,850 |
|
|
| 10,452 |
|
Contract assets — royalties and license fees |
| 7,796 |
|
|
| 7,116 |
|
Inventories, net |
| 14,839 |
|
|
| 11,819 |
|
Prepaids and other |
| 7,854 |
|
|
| 9,202 |
|
Total Current Assets |
| 86,691 |
|
|
| 57,587 |
|
Property and equipment, net |
| 26,026 |
|
|
| 27,148 |
|
Intangible assets, net |
| 26,206 |
|
|
| 28,145 |
|
Goodwill |
| 42,946 |
|
|
| 40,710 |
|
Other assets |
| 3,864 |
|
|
| 4,769 |
|
Total Assets | $ | 185,733 |
|
| $ | 158,359 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
| ||
Current Liabilities: |
|
|
|
|
| ||
Short-term borrowings |
| — |
|
|
| 10,000 |
|
Deferred revenue |
| 4,378 |
|
|
| 4,160 |
|
Other current liabilities |
| 19,576 |
|
|
| 17,919 |
|
Total Current Liabilities |
| 23,954 |
|
|
| 32,079 |
|
Long-term debt, net |
| 29,405 |
|
|
| — |
|
Deferred revenue |
| 2,400 |
|
|
| 5,088 |
|
Other long-term liabilities |
| 10,064 |
|
|
| 12,800 |
|
Total Liabilities |
| 65,823 |
|
|
| 49,967 |
|
Total Stockholders’ Equity |
| 119,910 |
|
|
| 108,392 |
|
Total Liabilities and Stockholders’ Equity | $ | 185,733 |
|
| $ | 158,359 |
|
|
|
|
|
|
| ||
Note: Derived from audited financial statements as of the date indicated. |
| ||||||
Surmodics, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
| Fiscal Year Ended September 30, | ||||||
| 2023 |
| 2022 | ||||
Operating Activities: |
|
|
|
|
| ||
Net loss | $ | (1,536 | ) |
| $ | (27,274 | ) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
|
| ||
Depreciation and amortization |
| 8,522 |
|
|
| 9,142 |
|
Stock-based compensation |
| 7,605 |
|
|
| 7,057 |
|
Deferred taxes |
| (181 | ) |
|
| 5,268 |
|
Other |
| 340 |
|
|
| 860 |
|
Change in operating assets and liabilities: |
|
|
|
|
| ||
Accounts receivable and contract assets |
| (977 | ) |
|
| (1,522 | ) |
Inventories |
| (3,020 | ) |
|
| (5,060 | ) |
Prepaids and other |
| — |
|
|
| (665 | ) |
Accounts payable |
| (183 | ) |
|
| 1,608 |
|
Accrued liabilities |
| (1,024 | ) |
|
| 132 |
|
Income taxes |
| 3,438 |
|
|
| (1,069 | ) |
Deferred revenue |
| (2,470 | ) |
|
| (5,700 | ) |
Net cash provided by (used in) operating activities |
| 10,514 |
|
|
| (17,223 | ) |
Investing Activities: |
|
|
|
|
| ||
Purchases of property and equipment |
| (2,918 | ) |
|
| (3,370 | ) |
Purchases of available-for-sale securities |
| (3,904 | ) |
|
| — |
|
Maturities of available-for-sale securities |
| — |
|
|
| 9,600 |
|
Net cash (used in) provided by investing activities |
| (6,822 | ) |
|
| 6,230 |
|
Financing Activities: |
|
|
|
|
| ||
Payments on short-term borrowings |
| (10,000 | ) |
|
| — |
|
Proceeds from issuance of long-term debt |
| 29,664 |
|
|
| — |
|
Payment of debt issuance costs |
| (614 | ) |
|
| — |
|
Issuance of common stock |
| 1,252 |
|
|
| 1,246 |
|
Payments for taxes related to net share settlement of equity awards |
| (918 | ) |
|
| (1,121 | ) |
Payments for acquisition of in-process research and development |
| (978 | ) |
|
| (500 | ) |
Net cash provided by (used in) financing activities |
| 18,406 |
|
|
| (375 | ) |
Effect of exchange rate changes on cash |
| 323 |
|
|
| (787 | ) |
Net change in cash and cash equivalents |
| 22,421 |
|
|
| (12,155 | ) |
Cash and Cash Equivalents: |
|
|
|
|
| ||
Beginning of year |
| 18,998 |
|
|
| 31,153 |
|
End of year | $ | 41,419 |
|
| $ | 18,998 |
|
Surmodics, Inc. and Subsidiaries
Supplemental Revenue Information
(in thousands)
(Unaudited)
| Three Months Ended |
|
|
|
| Fiscal 2023 vs. 2022 | |||||||||||||||||||||
| Dec 31, |
| Mar 31, |
| Jun 30, |
| Sep 30, |
| Fiscal |
| Increase (Decrease) | ||||||||||||||||
| 2022 |
| 2023 |
| 2023 |
| 2023 |
| 2023 |
| $ |
| % | ||||||||||||||
Medical Device Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Product sales | $ | 8,380 |
|
| $ | 7,914 |
|
| $ | 9,299 |
|
| $ | 8,533 |
|
| $ | 34,126 |
|
| $ | 6,196 |
|
|
| 22 | % |
Royalties & license fees – performance coatings |
| 7,469 |
|
|
| 8,098 |
|
|
| 8,286 |
|
|
| 8,959 |
|
|
| 32,812 |
|
|
| 2,265 |
|
|
| 7 | % |
License fees – SurVeil DCB(1) |
| 1,296 |
|
|
| 1,331 |
|
|
| 25,867 |
|
|
| 1,092 |
|
|
| 29,586 |
|
|
| 23,885 |
|
|
| 419 | % |
R&D and other |
| 1,873 |
|
|
| 2,364 |
|
|
| 2,562 |
|
|
| 2,460 |
|
|
| 9,259 |
|
|
| 1,048 |
|
|
| 13 | % |
Medical Device revenue |
| 19,018 |
|
|
| 19,707 |
|
|
| 46,014 |
|
|
| 21,044 |
|
|
| 105,783 |
|
|
| 33,394 |
|
|
| 46 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
In Vitro Diagnostics Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Product sales |
| 5,854 |
|
|
| 7,436 |
|
|
| 6,368 |
|
|
| 6,830 |
|
|
| 26,488 |
|
|
| (203 | ) |
|
| (1 | )% |
R&D and other |
| 61 |
|
|
| 55 |
|
|
| 101 |
|
|
| 96 |
|
|
| 313 |
|
|
| (558 | ) |
|
| (64 | )% |
In Vitro Diagnostics revenue |
| 5,915 |
|
|
| 7,491 |
|
|
| 6,469 |
|
|
| 6,926 |
|
|
| 26,801 |
|
|
| (761 | ) |
|
| (3 | )% |
Total Revenue | $ | 24,933 |
|
| $ | 27,198 |
|
| $ | 52,483 |
|
| $ | 27,970 |
|
| $ | 132,584 |
|
| $ | 32,633 |
|
|
| 33 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Medical Device revenue, excluding | $ | 17,722 |
|
| $ | 18,376 |
|
| $ | 20,147 |
|
| $ | 19,952 |
|
| $ | 76,197 |
|
| $ | 9,509 |
|
|
| 14 | % |
Total Revenue, excluding | $ | 23,637 |
|
| $ | 25,867 |
|
| $ | 26,616 |
|
| $ | 26,878 |
|
| $ | 102,998 |
|
| $ | 8,748 |
|
|
| 9 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
| Three Months Ended |
|
|
|
|
|
|
|
|
| |||||||||||||||||
| Dec 31, |
| Mar 31, |
| Jun 30, |
| Sep 30, |
| Fiscal |
|
|
|
|
|
| ||||||||||||
| 2021 |
| 2022 |
| 2022 |
| 2022 |
| 2022 |
|
|
|
|
|
| ||||||||||||
Medical Device Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Product sales | $ | 6,788 |
|
| $ | 6,441 |
|
| $ | 6,741 |
|
| $ | 7,960 |
|
| $ | 27,930 |
|
|
|
|
|
|
| ||
Royalties & license fees – performance coatings |
| 6,937 |
|
|
| 8,369 |
|
|
| 7,827 |
|
|
| 7,414 |
|
|
| 30,547 |
|
|
|
|
|
|
| ||
License fees – SurVeil DCB(1) |
| 1,162 |
|
|
| 1,475 |
|
|
| 968 |
|
|
| 2,096 |
|
|
| 5,701 |
|
|
|
|
|
|
| ||
R&D and other |
| 2,021 |
|
|
| 2,168 |
|
|
| 1,992 |
|
|
| 2,030 |
|
|
| 8,211 |
|
|
|
|
|
|
| ||
Medical Device revenue |
| 16,908 |
|
|
| 18,453 |
|
|
| 17,528 |
|
|
| 19,500 |
|
|
| 72,389 |
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
In Vitro Diagnostics Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Product sales |
| 5,556 |
|
|
| 7,523 |
|
|
| 7,178 |
|
|
| 6,434 |
|
|
| 26,691 |
|
|
|
|
|
|
| ||
R&D and other |
| 539 |
|
|
| 130 |
|
|
| 148 |
|
|
| 54 |
|
|
| 871 |
|
|
|
|
|
|
| ||
In Vitro Diagnostics revenue |
| 6,095 |
|
|
| 7,653 |
|
|
| 7,326 |
|
|
| 6,488 |
|
|
| 27,562 |
|
|
|
|
|
|
| ||
Total Revenue | $ | 23,003 |
|
| $ | 26,106 |
|
| $ | 24,854 |
|
| $ | 25,988 |
|
| $ | 99,951 |
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Medical Device revenue, excluding | $ | 15,746 |
|
| $ | 16,978 |
|
| $ | 16,560 |
|
| $ | 17,404 |
|
| $ | 66,688 |
|
|
|
|
|
|
| ||
Total Revenue, excluding | $ | 21,841 |
|
| $ | 24,631 |
|
| $ | 23,886 |
|
| $ | 23,892 |
|
| $ | 94,250 |
|
|
|
|
|
|
| ||
Surmodics, Inc. and Subsidiaries
Supplemental Segment Information
(in thousands)
(Unaudited)
| Three Months Ended September 30, |
| Fiscal Year Ended September 30, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Operating (Loss) Income: |
|
|
|
|
|
|
|
|
|
|
| ||||
Medical Device | $ | (2,399 | ) |
| $ | (6,211 | ) |
| $ | 5,084 |
|
| $ | (22,923 | ) |
In Vitro Diagnostics |
| 3,187 |
|
|
| 2,811 |
|
|
| 12,637 |
|
|
| 13,073 |
|
Total segment operating income (loss) |
| 788 |
|
|
| (3,400 | ) |
|
| 17,721 |
|
|
| (9,850 | ) |
Corporate |
| (3,238 | ) |
|
| (3,213 | ) |
|
| (12,571 | ) |
|
| (12,247 | ) |
Total (Loss) Income from Operations | $ | (2,450 | ) |
| $ | (6,613 | ) |
| $ | 5,150 |
|
| $ | (22,097 | ) |
Surmodics, Inc. and Subsidiaries
Reconciliation of GAAP Measures to Non-GAAP Amounts
Schedule of EBITDA and Adjusted EBITDA
(in thousands)
(Unaudited)
| Three Months Ended September 30, |
| Fiscal Year Ended September 30, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Net Income (Loss) | $ | 6,694 |
|
| $ | (14,728 | ) |
| $ | (1,536 | ) |
| $ | (27,274 | ) |
Income tax (benefit) expense |
| (9,483 | ) |
|
| 7,936 |
|
|
| 4,023 |
|
|
| 4,781 |
|
Depreciation and amortization |
| 2,157 |
|
|
| 2,240 |
|
|
| 8,522 |
|
|
| 9,142 |
|
Interest expense, net |
| 895 |
|
|
| 188 |
|
|
| 3,489 |
|
|
| 598 |
|
Investment income, net |
| (546 | ) |
|
| (26 | ) |
|
| (1,077 | ) |
|
| (99 | ) |
EBITDA |
| (283 | ) |
|
| (4,390 | ) |
|
| 13,421 |
|
|
| (12,852 | ) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Adjustments: |
|
|
|
|
|
|
|
|
|
|
| ||||
Stock-based compensation expense |
| 1,943 |
|
|
| 1,859 |
|
|
| 7,605 |
|
|
| 7,057 |
|
Restructuring expense(2) |
| — |
|
|
| — |
|
|
| 1,282 |
|
|
| — |
|
Contingent consideration fair value adjustment(3) |
| — |
|
|
| — |
|
|
| (829 | ) |
|
| — |
|
Adjusted EBITDA | $ | 1,660 |
|
| $ | (2,531 | ) |
| $ | 21,479 |
|
| $ | (5,795 | ) |
Surmodics, Inc. and Subsidiaries
Net Income (Loss) and Diluted EPS GAAP to Non-GAAP Reconciliation
(in thousands, except per share data)
(Unaudited)
| For the Three Months Ended September 30, 2023 | ||||||||||||||||||
| Operating Loss |
| Loss Before Income Taxes |
| Net Income(6) |
| Diluted EPS | ||||||||||||
GAAP | $ | (2,450 | ) |
|
| (8.8 | )% |
| $ | (2,789 | ) |
| $ | 6,694 |
|
| $ | 0.47 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
Amortization of acquired intangible assets(4) |
| 878 |
|
|
| 3.2 | % |
|
| 878 |
|
|
| 812 |
|
|
| 0.06 |
|
Non-GAAP | $ | (1,572 | ) |
|
| (5.6 | )% |
| $ | (1,911 | ) |
| $ | 7,506 |
|
| $ | 0.53 |
|
Diluted weighted average shares |
|
|
|
|
|
|
|
|
|
|
|
|
| 14,152 |
| ||||
| For the Three Months Ended September 30, 2022 |
| |||||||||||||||||
| Operating Loss |
| Loss Before Income Taxes |
| Net Loss(6) |
| Diluted EPS | ||||||||||||
GAAP | $ | (6,613 | ) |
|
| (25.4 | )% |
| $ | (6,792 | ) |
| $ | (14,728 | ) |
| $ | (1.06 | ) |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
Amortization of acquired intangible assets(4) |
| 966 |
|
|
| 3.7 | % |
|
| 966 |
|
|
| 906 |
|
|
| 0.07 |
|
Tax expense from full valuation allowance |
| — |
|
|
| — |
|
|
| — |
|
|
| 10,151 |
|
|
| 0.73 |
|
Non-GAAP | $ | (5,647 | ) |
|
| (21.7 | )% |
| $ | (5,826 | ) |
| $ | (3,671 | ) |
| $ | (0.26 | ) |
Diluted weighted average shares |
|
|
|
|
|
|
|
|
|
|
|
|
| 13,944 |
| ||||
| Fiscal Year Ended September 30, 2023 |
| |||||||||||||||||
| Operating Income |
| Income Before Income Taxes |
| Net (Loss) Income(6) |
| Diluted EPS | ||||||||||||
GAAP | $ | 5,150 |
|
|
| 3.9 | % |
| $ | 2,487 |
|
| $ | (1,536 | ) |
| $ | (0.11 | ) |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
Amortization of acquired intangible assets(4) |
| 3,537 |
|
|
| 2.6 | % |
|
| 3,537 |
|
|
| 3,279 |
|
|
| 0.24 |
|
Restructuring expense(2) |
| 1,282 |
|
|
| 1.0 | % |
|
| 1,282 |
|
|
| 1,282 |
|
|
| 0.09 |
|
Contingent consideration fair value |
| (829 | ) |
|
| (0.6 | )% |
|
| (829 | ) |
|
| (829 | ) |
|
| (0.06 | ) |
Non-GAAP | $ | 9,140 |
|
|
| 6.9 | % |
| $ | 6,477 |
|
| $ | 2,196 |
|
| $ | 0.16 |
|
Diluted weighted average shares |
|
|
|
|
|
|
|
|
|
|
|
|
| 14,071 |
| ||||
| Fiscal Year Ended September 30, 2022 |
| |||||||||||||||||
| Operating Loss |
| Loss Before Income Taxes |
| Net Loss(6) |
| Diluted EPS | ||||||||||||
GAAP | $ | (22,097 | ) |
|
| (22.1 | )% |
| $ | (22,493 | ) |
| $ | (27,274 | ) |
| $ | (1.96 | ) |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
Amortization of acquired intangible assets(4) |
| 4,150 |
|
|
| 4.1 | % |
|
| 4,150 |
|
|
| 3,888 |
|
|
| 0.28 |
|
Tax expense from full valuation allowance |
| — |
|
|
| — |
|
|
| — |
|
|
| 10,151 |
|
|
| 0.73 |
|
Non-GAAP | $ | (17,947 | ) |
|
| (18.0 | )% |
| $ | (18,343 | ) |
| $ | (13,235 | ) |
| $ | (0.95 | ) |
Diluted weighted average shares |
|
|
|
|
|
|
|
|
|
|
|
|
| 13,916 |
| ||||
Surmodics, Inc. and Subsidiaries
Guidance Reconciliation: Estimated Revenue
For the Fiscal Year Ending September 30, 2024
(in millions)
(Unaudited)
| Fiscal 2024 Full-Year Estimate |
| Increase (Decrease) |
|
|
| |||||||||||||
| Low |
| High |
| Low |
| High |
| Fiscal 2023 | ||||||||||
Total Revenue | $ | 116 |
|
| $ | 121 |
|
|
| (13 | )% |
|
| (9 | )% |
| $ | 133 |
|
License fees – SurVeil DCB(1) |
| (4 | ) |
|
| (4 | ) |
|
| (86 | )% |
|
| (86 | )% |
|
| (30 | ) |
Total Revenue, excluding SurVeil DCB license fees(1) | $ | 112 |
|
| $ | 117 |
|
|
| 9 | % |
|
| 14 | % |
| $ | 103 |
|
Surmodics, Inc. and Subsidiaries
Guidance Reconciliation: Estimated Non-GAAP Diluted EPS
For the Fiscal Year Ending September 30, 2024
(shares in thousands)
(Unaudited)
| Fiscal 2024 Full-Year Estimate | ||||||
| Low |
| High | ||||
GAAP Diluted EPS | $ | (1.55 | ) |
| $ | (1.20 | ) |
Amortization of acquired intangibles per diluted share(4) |
| 0.23 |
|
|
| 0.23 |
|
Non-GAAP Diluted EPS | $ | (1.32 | ) |
| $ | (0.97 | ) |
Diluted weighted average shares outstanding |
| 14,150 |
|
|
|
| |
(1) | SurVeil DCB license fee revenue represents revenue recognition on milestone payments received under the company’s Development and Distribution Agreement with Abbott (“Abbott Agreement”). | |
(2) | Restructuring expense consists of severance and related costs specifically associated with a workforce restructuring implemented in the second quarter of fiscal 2023. | |
(3) | Represents accounting adjustments to state acquisition-related contingent consideration liabilities at their estimated fair value as of the period end date, including adjustments to the liabilities’ fair values related to changes in the timing and/or probability of achieving milestones and accretion expense for the passage of time. | |
(4) | Represents amortization of business acquisition-related intangible assets and associated tax impact. A significant portion of the business acquisition-related amortization is not tax deductible. | |
(5) | Represents the non-cash charge to income tax expense that resulted from the establishment of a full valuation allowance against U.S. net deferred tax assets in the fourth quarter of fiscal 2022. A valuation allowance is required to be recognized against deferred tax assets if, based on the available evidence, it is more likely than not (defined as a likelihood of more than 50%) that all or a portion of such assets will not be realized. The relevant guidance weighs available evidence such as historical cumulative taxable losses more heavily than future profitability. The valuation allowance has no impact on the availability of U.S. net deferred tax assets to offset future tax liabilities. | |
(6) | Net income (loss) includes the effect of the above adjustments on income tax benefit (expense), taking into account deferred taxes net of valuation allowances, as well as non-deductible items. Income tax impacts were estimated using the applicable statutory rate (21% in the U.S. and 12.5% in Ireland). | |
(7) | Diluted weighted average shares outstanding used in the calculation of EPS was the same for GAAP EPS and Non-GAAP EPS for the three months ended September 30, 2023 and 2022 and the fiscal year ended September 30, 2022. For the fiscal year ended September 30, 2023, diluted weighted average shares outstanding used in the calculation of EPS was 14,031 for GAAP EPS due to the net loss in the period, and 14,071 for Non-GAAP EPS corresponding to the Non-GAAP net income in the period. |
| Last Trade: | US$39.70 |
| Daily Change: | -0.26 -0.65 |
| Daily Volume: | 66,357 |
| Market Cap: | US$568.900M |
November 06, 2024 October 30, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
